CagriSema REDEFINE: What Novo Nordisk's Amylin Combination Actually Showed

CagriSema is Novo Nordisk's next-generation injectable weight-loss combination — cagrilintide (an amylin analog) plus semaglutide 2.4 mg (the same GLP-1 agonist already marketed as Wegovy). The hypothesis is mechanistic: amylin and GLP-1 are independent appetite-regulating gut hormones with non-overlapping receptor systems, so combining them should produce additive weight loss beyond what either alone can deliver. The REDEFINE 1 phase 3 trial in adults with overweight or obesity (no diabetes) and the REDEFINE 2 trial in adults with type 2 diabetes have now both reported results [3, 4]. CagriSema produced the largest weight loss ever shown for an injectable combination of approved or near-approved drugs, but it missed the ~25% benchmark Novo Nordisk had previously guided investors toward, which dented the market reaction. This article walks through the verified REDEFINE 1 and REDEFINE 2 data, the mechanism, the safety profile, and what CagriSema actually represents in the evolving GLP-1 landscape.

What CagriSema actually is

Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic β-cells in response to meals. Amylin slows gastric emptying, suppresses postprandial glucagon release, and signals satiety in the area postrema and other hindbrain regions — pathways that are mechanistically distinct from the GLP-1 signaling system. The phase 1b combination study (Enebo et al., Lancet 2021 [5]) and the phase 2 cagrilintide monotherapy trial (Lau et al., Lancet 2021 [6]) established the clinical signal that motivated REDEFINE.

CagriSema is a fixed-combination once-weekly subcutaneous injection delivering cagrilintide plus semaglutide 2.4 mg, titrated together over the standard ~16-week ramp.

REDEFINE 1: adults with overweight or obesity (no diabetes)

REDEFINE 1 is the pivotal phase 3 trial in the population most analogous to the existing Wegovy indication. Verified design and results from Novo Nordisk's December 2024 Company Announcement [3]:

• Sample size: approximately 3,400 adults randomized
• Population: overweight or obesity with ≥1 weight-related comorbidity, no type 2 diabetes
• Arms: CagriSema, cagrilintide alone, semaglutide 2.4 mg alone, placebo
• Duration: 68 weeks
• Primary endpoint: percent change in body weight from baseline

Two important things happened in REDEFINE 1 [3]:

1. Additive benefit confirmed. CagriSema produced ~5.5 percentage points more weight loss than semaglutide alone and ~8.9 pp more than cagrilintide alone, on the full ITT analysis. Both component drugs contributed independently. The hypothesis behind the combination held up.
2. Missed the 25% target. Novo Nordisk had previously guided investors that CagriSema could plausibly hit ~25% mean weight loss. The actual mean of ~20.4% (full ITT) and ~22.7% (adherent) is meaningful but fell short of that bar, and the stock dropped sharply on the readout. The clinical relevance is that CagriSema beats semaglutide alone but does not match the tirzepatide effect size from SURMOUNT-1 (~20.9% at 72 weeks).

Novo Nordisk also reported that 40.4% of CagriSema-treated participants achieved ≥25% weight loss, and 50.7% of the CagriSema arm reached a BMI below 30 [3]. Both of these responder-rate numbers are best-in-class for an injectable.

REDEFINE 2: adults with type 2 diabetes

REDEFINE 2 evaluated CagriSema in adults with overweight or obesity AND type 2 diabetes. The trial population is important because patients with T2D consistently lose less weight on GLP-1 agonists than non-diabetic patients — the SURMOUNT-2 trial of tirzepatide showed roughly 15% weight loss at the highest dose in T2D vs the ~20% in SURMOUNT-1 non-diabetic [1]. The full REDEFINE 2 publication appeared in NEJM in 2025 [2]. Verified results:

The REDEFINE 2 effect size is smaller than REDEFINE 1, but the absolute placebo-adjusted weight loss (~10.3 pp) is consistent with what other GLP-1 agonists have produced in T2D populations and is clinically meaningful for patients managing both obesity and type 2 diabetes. The full glycemic and cardiometabolic results are in the NEJM publication [2].

Why mechanism matters

Until CagriSema, the most successful obesity drugs all targeted variations on the incretin axis: GLP-1 alone (semaglutide), GLP-1 + GIP (tirzepatide), or in development GLP-1 + GIP + glucagon (retatrutide). CagriSema is the first late-stage program to add a fundamentally different appetite-suppression mechanism — amylin signaling — to a GLP-1 backbone.

That mechanistic distinction is important because:

1. The two pathways are independent, so combining them should produce additive (not redundant) appetite suppression — and the REDEFINE 1 component-arm data confirmed this.
2. The amylin pathway has different downstream effects on glycemic control, gastric emptying, and CNS signaling than incretin pathways, which opens new questions about long-term metabolic adaptation, food-reward signaling, and the durability of weight loss.
3. Future combinations could plausibly stack amylin + GLP-1 + GIP or amylin + GLP-1 + GIP + glucagon, which would be the first “quadruple agonist” generation of obesity therapeutics.

Safety profile

Both REDEFINE trials reported a safety profile broadly consistent with the established GLP-1 class — predominantly gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation), predominantly mild to moderate, predominantly resolving with continued use [3, 4]. The cagrilintide component appears to add modestly to the GI burden without introducing new categories of adverse events.

The full safety datasets are documented in the published manuscripts and the Novo regulatory submissions. As with any new injectable obesity drug, post-marketing experience and longer-term observational data will refine the rare-event picture. The standard GLP-1 class warnings (thyroid C-cell tumors, pancreatitis, gallbladder disease, retinopathy in T2D, dehydration-induced kidney injury) are expected to apply.

Where CagriSema fits in 2026

Novo Nordisk has filed a New Drug Application with the FDA for CagriSema. Timing of approval is the next major catalyst. Assuming approval, the practical positioning for CagriSema looks like this:

CagriSema is competitive with tirzepatide on effect size, comes from a different mechanistic family, and gives Novo Nordisk a lead in the post-Wegovy generation. It is unlikely to displace tirzepatide as the highest-effect- size injectable, but it expands the menu and creates a meaningful second option for patients who don't respond to or tolerate tirzepatide.

Open questions

1. Pricing. CagriSema launch pricing has not been announced. Novo will need to price this product competitively against tirzepatide and the newly-approved oral Foundayo.
2. Cardiovascular outcomes. A SELECT-style outcomes trial of CagriSema has not been announced. Until CagriSema accumulates its own cardiovascular outcomes evidence, Wegovy retains an edge for patients with established cardiovascular disease (see our SELECT trial deep-dive).
3. Long-term durability. 68 weeks is the published duration. Whether the additive amylin benefit is sustained over multi-year therapy, and what happens to the weight loss after discontinuation, has not been published.
4. Direct head-to-head with tirzepatide. REDEFINE did not include a tirzepatide arm. Without a direct comparison, all CagriSema-vs-tirzepatide claims are inferential.

Related research

For the broader injectable GLP-1 landscape, see our tirzepatide vs semaglutide head-to-head deep-dive, the Foundayo (oral orforglipron) approval analysis, and the retatrutide triple-agonist evidence review. For the cardiovascular outcomes data on injectable semaglutide that anchors the existing standard of care, see our SELECT trial deep-dive. For pricing context across the entire GLP-1 market, see our pricing index.